SHERIDAN, WYOMING - April 3, 2026 - Institutional investors evaluating healthcare distribution and dental supply chains gain a direct window into Henry Schein's strategic priorities as the company presents at two major sell-side healthcare conferences, signaling where management attention is focused for 2026 capital allocation and operational direction.
Conference participation details
Henry Schein, Inc. (Nasdaq: HSIC) presented at Leerink's Global Healthcare Conference at the W South Beach hotel in Miami on March 9, with a session starting at 10:00 a.m. EST. The following day, March 10, the company appeared at the Barclays 28th Annual Global Healthcare Conference, held at the Loews Miami Beach hotel, also in Miami, beginning at 10:30 a.m. EST.
Both presentations were made available via live webcast through the company's investor relations portal at www.henryschein.com/IRwebcasts. Replay recordings were subsequently posted to the Henry Schein website, extending access to investors and analysts unable to attend in real time. The back-to-back scheduling in Miami during a single week concentrated management availability and signaled deliberate engagement with the institutional healthcare investment community.
Henry Schein's scale and market position
Henry Schein operates as the largest provider of healthcare solutions to office-based dental and medical practitioners globally. The company employs more than 25,000 Team Schein Members worldwide and serves over one million customers across more than 300 distinct solutions spanning clinical, business, technology, and supply chain functions. Its distribution centers carry more than 300,000 branded and Henry Schein corporate brand products.
The company reported $13.2 billion in sales for 2025, representing a compound annual growth rate of approximately 11 percent since its 1995 public listing. Henry Schein holds FORTUNE 500 and S&P 500 membership and maintains operations or affiliates across 34 countries and territories. Its centralized and automated distribution network supports not only private dental and medical offices but also dental laboratories, government health clinics, and alternate care sites.
Investor relations posture and 2026 signals
Participation in both the Leerink and Barclays events reflects Henry Schein's sustained engagement with sell-side and buy-side healthcare analysts at a period when dental and medical supply chain economics are under scrutiny. With $13.2 billion in 2025 revenue and an 11 percent compounded growth trajectory, investor presentations in early 2026 carry weight for analysts modeling near-term organic growth, margin structure, and capital deployment priorities.
Management access through Ronald N. South, Senior Vice President and Chief Financial Officer, and Graham Stanley, Vice President of Investor Relations and Strategic Financial Project Officer, frames these events as substantive financial dialogue rather than routine calendar appearances. The CFO-level presence at both conferences underscores that the conversations likely addressed financial guidance, distribution network investment, and technology-enabled solutions strategy.
Business impact
Procurement leads and supply chain officers within dental group practices, dental service organizations (DSOs), and medical office networks should monitor the positions articulated at these conferences to anticipate pricing, product availability, and service model changes. When a distributor of Henry Schein's scale presents strategy to institutional investors, subsequent shifts in vendor terms, distribution prioritization, or technology bundling often follow within one to two quarters.
Portfolio managers and healthcare equity analysts at investment firms must now factor in Henry Schein's 2026 growth signals against the backdrop of a $13.2 billion revenue base. The company's 34-country footprint and 300,000-SKU distribution capability make it a bellwether for dental supply chain health globally - conference disclosures often set consensus expectations that influence procurement budgets across the broader dental and medical office market. Technology evaluation teams inside DSOs and hospital group purchasing organizations (GPOs) should track any technology solution announcements from these sessions, as Henry Schein's software and clinical workflow offerings are increasingly embedded in practice management infrastructure.